Tyromotion presents outstanding business results in the second quarter of 2023, along with a new product line for medical training therapy (MTT-LINE).
Record-breaking revenue growth of +225%
Austria-based medical technology manufacturer Tyromotion concluded in June 2023 its highest revenue-generating quarter since its establishment. CEO Siegfried Schabel and CTO Alexander Kollreider are delighted with a revenue record that exceeds the planned budget by approximately 10%. Compared to the previous year, the company has more than doubled its sales (+225%).
“We are the preferred partner in neurological rehabilitation for our customers and distributors. Tyromotion has been growing steadily since its founding 16 years ago. This is a sign that we are doing something right, but it also brings numerous challenges and tremendous opportunities.” CEO Siegfried Schabel
Medical training therapy complements the product portfolio
Since its establishment, Tyromotion has consistently introduced new products to the market and established TYROTHERAPY as a comprehensive concept for neurorehabilitation. This concept has now been expanded with a series of medical training devices that complement the existing product portfolio. The medical devices for targeted strength training support patients in their rehabilitation process and are wheelchair-accessible, ensuring accessibility for individuals with disabilities. The pneumatic training system impresses with its silent operation, individually adjustable resistance levels, and realistic simulation of physiological muscle function.
The internationally respected expert in neurorehabilitation, Sabine Lamprecht, has endorsed these products positively. “Targeted strength training is essential in neurological rehabilitation. Patients with conditions such as stroke, Multiple Sclerosis, spinal cord injury, or Parkinson’s disease benefit from targeted strength training in their everyday lives. Medical training therapy leads to increased physical endurance, improved walking and balance, and reduces the risk of falls.” Sabine Lamprecht, PT, MSc. Neurorehabilitation
Further product innovations for 2023
The leadership duo, consisting of CEO Siegfried Schabel and CTO Alexander Kollreider, remains optimistic about the future. “The success of our company and the outstanding performance of our employees are the result of our shared vision, hard work, and strong teamwork,” emphasized CTO Alexander Kollreider.
The continuous advancements of our existing products are particularly exciting. The gait trainer OMEGO® has been equipped with new pedals for ankle training, while AMADEO® has received an additional EMG module. Furthermore, the robotic gait trainer LEXO® now includes the pediatric set, allowing its use for children above 100 cm in height. Further product innovations for TYMO® and PABLO® are planned in 2023.
CEO Siegfried Schabel and CTO Alexander Kollreider
About Tyromotion
Tyromotion`s vision is to sustainably improve people’s independence and quality of life. By using state-of-the-art technologies such as robotics, sensor technology, virtual reality, and gamification, patients are accompanied through the rehabilitation process in an effective and motivating way. With over 80 employees, 40 distribution partners, and a reinvestment rate of 20% in research and development, Tyromotion ensures innovation at the highest level.
Press Contact
Text and images: ©Tyromotion
PDF-Version